BOSTON, MA, Feb 17, 2026 - (ACN Newswire) - Bioxytran, Inc. (OTCMKTS: BIXT) (“Bioxytran” or the “Company”), a biotechnology company developing galectin-targeting carbohydrate technologies with applications across infectious disease, metabolic health, and inflammation, today announced that it has entered into a commercial Distribution Agreement with Khoury Medical LTD (“Khoury Medical”), a company focused on the development and commercialization of plant-derived dietary supplements.

Under the agreement, Khoury Medical will commercialize A-SUQAR®, a chewable dietary supplement containing Bioxytran’s proprietary partially hydrolyzed guar gum (PHGG) formulation, in permitted markets in accordance with the Distribution Agreement. The product is marketed as a dietary supplement intended to support healthy post-meal blood sugar levels, consistent with applicable regulatory requirements.

“This agreement represents an important milestone for Bioxytran as we transition from a development-stage organization to a company with recurring commercial revenue,” said David Platt, Chief Executive Officer of Bioxytran. “A-SUQAR® provides real-world market validation of our proprietary carbohydrate-based galectin platform, while preserving our ability to advance higher-value pharmaceutical and antiviral programs.”

Bioxytran’s recent positive Phase 2 clinical results with ProLectin-M, its investigational antiviral candidate, further validate the Company’s proprietary carbohydrate-based galectin platform. The same foundational galectin-targeting science underpins both its pharmaceutical development programs and select nutraceutical applications, demonstrating the breadth of potential applications for this technology.

The Distribution Agreement provides the potential for earned, volume-based marketplace exclusivity, subject to defined purchase thresholds and conditions set forth in the Distribution Agreement. Manufacturing will be performed by Bioxytran’s designated OEM, with regulatory registration, marketing, and distribution execution led by Khoury Medical, allowing Bioxytran to maintain a capital-efficient commercial model while retaining full ownership of its intellectual property.

“This collaboration allows us to bring a differentiated, science-informed product with the potential for broader market expansion, subject to applicable agreements and regulatory requirements,” said Nassar Khoury, CEO of Khoury Medical LTD. “We believe A-SUQAR® addresses a meaningful consumer need, and we look forward to building a successful commercial launch together with Bioxytran.”

Importantly, the agreement is structured to apply solely to non-pharmaceutical dietary products, preserving Bioxytran’s ability to independently advance and partner its technology for pharmaceutical, antiviral, and other clinical development applications.

The parties expect initial commercial shipments to commence following completion of standard launch preparations and are addressing a sizable global market demand for the A-SUQAR Line.